Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Group B Streptococcus Vaccine (GBS-NN/NN2) in Women Who Are Pregnant and Living With HIV and Women Who Are Pregnant and do Not Have HIV

Next Previous
Trial Profile

A Multi-centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Group B Streptococcus Vaccine (GBS-NN/NN2) in Women Who Are Pregnant and Living With HIV and Women Who Are Pregnant and do Not Have HIV

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GBS NN (Primary) ; Aluminium hydroxide
  • Indications Streptococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Minervax

Most Recent Events

  • 08 Jun 2023 Status changed from active, no longer recruiting to completed.
  • 12 Feb 2022 Status changed from recruiting to active, no longer recruiting.
  • 07 Oct 2021 According to a Minervax media release, the company enrolment of 150 pregnant women in this study in South Africa and dosing of an additional 50 pregnant women in the same study has started in Uganda.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top